Read our latest updates & insights

Biocon and Evotec announce strategic licensing agreement for an early-stage biosimilar. Under this agreement, Biocon will take the asset through end-to-end development, IND filing, manufacturing and commercialisation and post-regulatory approval.

Roche announces results of Phase III clinical trials of MabThera/Rituxan® compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). Roche has announced that the results demonstrate Rituxan’s superiority over MMF for PV patients...

Polpharma publishes details of upcoming phase III clinical trials of biosimilar natalizumab candidate. The study will involve approximately 260 patients with relapsing-remitting multiple sclerosis.

Prestige releases details of upcoming Phase III clinical trials of biosimilar bevacizumab candidate.

Alteogen announces Phase I clinical trials of biosimilar aflibercept candidate will begin this month.

Lupin announces plans to file applications for biosimilar etanercept in the US market by the fourth quarter of FY20.

Samsung Bioepis releases results of Benepali® psoriasis study, announcing results demonstrate the product’s effectiveness and safety in a real-world setting. The study was conducted by the British Association of Dermatologists, Biologics and Immunomodulators Registry ...

The Institute for Clinical and Economic Review releases its report on Unsupported Price Increases, highlighting AbbVie’s Humira® as one of the products with price increases which are unsupported by new clinical evidence. 

The Institute for Clinical and Economic Review releases its report on Unsupported Price Increases, highlighting Roche’s Rituxan® as one of the products with price increases which are unsupported by new clinical evidence.